Application of the SARS-CoV-2-S1 ACE-2 receptor interaction as the basis of the fully automated assay to detect neutralizing SARS-CoV-2-S1 antibodies in blood samples.
JSON
Filchtinski D, Sundberg M, Berthold H, Steller L, Kayser J, Holz S, Hinze M, Braeutigam O, Schulte-Pelkum J, Fiedler R
J Immunol Methods 504 (-) 113258 [2022-03-15; online 2022-03-15]
A quantitative, high throughput, fully automated diagnostic method for the detection of neutralizing anti-SARS-CoV-2 antibodies was developed on the Phadia system based on the interaction of SARS-CoV-2 S1 protein and the human ACE-2 receptor. This method was compared to the current state of the art plaque reduction neutralization test (PRNT) and a high correlation between the two methods was observed. Using a large cohort of blood samples from convalescent patients and controls the method displays very high sensitivity and specificity (99,8% and 99.99%, respectively). Neutralizing antibody titers of mRNA-1273 and BNT162b2-vaccinated persons can also be quantified with this method as well. This fully automated method provides the possibility to determine anti-SARS-CoV-2 neutralizing antibody concentrations in just 2 h.
PubMed 35304119
DOI 10.1016/j.jim.2022.113258
Crossref 10.1016/j.jim.2022.113258
pii: S0022-1759(22)00045-X
pmc: PMC8923036